Adverse Outcome Pathway on Cyp2E1 activation leading to liver cancer

Francina Webster, Iain B. Lambert and Carole L. Yauk
Additional contact information
Francina Webster: Health Canada
Iain B. Lambert: Carleton University
Carole L. Yauk: University of Ottawa

No 19, OECD Series on Adverse Outcome Pathways from OECD Publishing

Abstract: The present AOP describes the prolonged activation of Cyp2E1 resulting in liver cancer. Cyp2E1 is a cytochrome P450 mono-oxygenase that bioactivates over 85 substrates, thereby creating electrophilic metabolites and oxidative stress. Mono-oxygenation of these substrates to their reactive metabolites, and the accompanying oxidative stress produced during metabolism, pose health risks because they lead to hepatotoxicity and, often, to liver cancer. The MIE occurs when Cyp2E1 binds a substrate. The Cyp2E1 catalytic cycle is prone to decoupling, which produces oxidative stress (KE1), and mono-oxidation of substrates produces reactive metabolites. Both reactive oxygen species and metabolites cause cytotoxicity (KE2). However, following injury, the liver is able to regenerate itself through an increase in cellular proliferation (KE3). Under conditions of chronic activation of Cyp2E1, excessive chronic increases in levels of reactive oxygen species and cell death, and subsequent dysregulated cellular proliferation, leads to tumour formation (AO).

Date: 2021-10-15
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://doi.org/10.1787/56e9bbf0-en (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oec:envaad:19-en

Access Statistics for this paper

More papers in OECD Series on Adverse Outcome Pathways from OECD Publishing Contact information at EDIRC.
Bibliographic data for series maintained by ().